All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
11 warning events since 2017; the latest 2026-08-21.
From the record
Citius Pharmaceuticals, Inc.'s filings since 2017 show 11 warning events: a notice about its exchange listing (8-K item 3.01, 11 times, the latest 2026-08-21) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+12.5% a year over 6 filed years; profitable in 0 of 6.
From the record
Citius Pharmaceuticals, Inc.'s 6 filed years say what it did: revenue went from $50 thousand in fiscal 2017 to $90 thousand in fiscal 2022, up 12.5% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 0 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 4.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Citius Pharmaceuticals, Inc.'s shareholder treatment is put at 4.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 46% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -59%: lost 59¢ per shareholder dollar. Leverage 48%: owes 48¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-09-30, Citius Pharmaceuticals, Inc. lost about 59 cents for every dollar of shareholders' money. Leverage: it owed about 48 cents per dollar of assets, and net share issuance: its share count grew 64.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 17% of 315 in its family; net margin -37378.5%.
From the record
Citius Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $90 thousand in fiscal 2022 ranks in the bottom 8% by size; a net margin of -37378.5% ranks in the bottom 6%; revenue growth of 0% a year over the last 3 filed years ranks in the bottom 38% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 3.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Citius Pharmaceuticals, Inc.'s leadership is put at 3.3 of 10 with a confidence of 35 of 100, because read from one part only, the chief executive's years under the title, which ranks in the bottom 33% of 415 in its family; fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
SI estimate 1.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Citius Pharmaceuticals, Inc.'s room to expand is put at 1.7 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 17% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
bottom 42% of 306 in its family for growth drivers.
From the record
Citius Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2022: revenue grew 0% a year over the last three filed years against 12.5% over all 6, slowing (bottom 30% of its family); the newest year grew 0% (bottom 38%); research spending grew -19.7% a year (bottom 18%); capital spending grew 34.4% a year (top 19%) (its annual reports). Citius Pharmaceuticals, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 26% of 233 in its family for expectations against reality.
From the record
Citius Pharmaceuticals, Inc.'s newest year against its own record: revenue of $90 thousand in fiscal 2022 came in 0% above the $90 thousand its prior three years' pace pointed to (top 46% of its family); net income of $34 million against a prior three-year average of $19 million (bottom 18%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 4%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made